Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Interactions between sleep, inflammation, immunity and infections: A narrative review.
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections.
The immunology of sickness metabolism.
Inflammation unites diverse acute and chronic diseases.
The global role of G6PD in infection and immunity.
Microalgae-made human vaccines and therapeutics: A decade of advances.
Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment.
Smoking changes adaptive immunity with persistent effects.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
gcPathogen: a comprehensive genomic resource of human pathogens for public health.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 regulatory approval from EMA on record.
- 4 clinical trials expected to report results, the earliest in Q1 2028.
- 3 industry developments reported.
- Q1 2028A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age
- Q4 2028A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.
- Q2 2029Randomized Controlled Trial Comparing an Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.
- Q4 2030Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled Trial
Clinical MilestonesViewHide
- 2026-03-19A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
- 2025-08-22A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
- 2026-07-01Randomized Controlled Trial Comparing an Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.Results expected Q2 2029
- 2026-06-22A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.Results expected Q4 2028
- 2026-06-02A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of AgeResults expected Q1 2028
- 2026-05-08Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled TrialResults expected Q4 2030
Industry & MarketViewHide
- 2026-07-30How one amino acid might help fight colon cancer and infectionsIndustry · Science News
- 2026-07-10Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida InfectionsIndustry · GEN News
- 2026-04-07This diet could slash cholera infections by up to 100xIndustry · Science Daily
Regulatory UpdatesViewHide
- 2026-04-27Approval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
- 2026-07-30IndustryHow one amino acid might help fight colon cancer and infectionsIndustry · Science News
- 2026-07-10IndustryMacrophage Membrane-Derived Nanoparticles Shows Potential Against Candida InfectionsIndustry · GEN News
- 2026-07-01ClinicalRandomized Controlled Trial Comparing an Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.Results expected Q2 2029
- 2026-06-22ClinicalA Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.Results expected Q4 2028
- 2026-06-02ClinicalA Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of AgeResults expected Q1 2028
- 2026-05-08ClinicalEffect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled TrialResults expected Q4 2030
- 2026-04-27RegulatoryApproval — MavorixaforXolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
- 2026-04-07IndustryThis diet could slash cholera infections by up to 100xIndustry · Science Daily
- 2026-03-19ClinicalA Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
- 2025-08-22ClinicalA Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syn… (2026)
Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)
Approval — Tecovirimat SIGA is indicated for the treatment of the following viral infections in adul… (2022)
Approval — Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM)… (2020)
Approval — Tygecycline Accord is indicated in adults and in children from the age of eight years for… (2020)
Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)
Approval — Posaconazole Accord is indicated for use in the treatment of the following fungal infecti… (2019)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Infections5
- Immunity, Innate2
- Inflammation2
- Adaptation, Physiological1
- Adaptive Immunity1
- Anorexia1
- Antigens, CD191
- Cardiovascular Diseases1
Leading journals6
- Frontiers in immunology3
- Nature3
- Annual review of immunology2
- Cellular & molecular immunology2
- Annals of internal medicine1
- Biotechnology journal1
Leading researchers8
- Aggarwal BB1
- Aigner M1
- Albert ML1
- Anand P1
- Andersson U1
- Angulo C1
- Anzueto A1
- Ardura MI1
Affiliations (unnormalised)6
- 2nd Department of Medicine and Cardiology Centre1
- Aarhus University Hospital1
- Acibadem City Clinic Tokuda Hospital1
- Africa Centres for Disease Control and Prevention1
- Aix Marseille Université1
- and the Institute of Clinical Microbiology1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Infections are conditions caused by invasion of the host by microorganisms, their toxins, or parasites that can produce pathological disease. The literature grounding frames infections broadly across microbiology, parasitology, virology, immunology, diagnosis, therapy, metabolism, and complications.
Infections are caused by invasion with microorganisms, their toxins, or parasites. The supplied grounding also links infections with pathogen-derived molecules that stimulate innate immune responses.
The grounding emphasizes host innate immune activation as a central mechanism in infection. CRP is described as an acute inflammatory protein that rises at sites of infection and participates in complement, apoptosis, phagocytosis, nitric oxide release, and production of inflammatory mediators, while HMGB1 is presented as a mediator of innate immune signaling through TLR4 that drives cytokine release and tissue damage. The microbiome and mucus barrier are also highlighted as part of host defense at mucosal surfaces.
The supplied grounding does not support a specific list of risk factors for infections. It does note associations with smoking, diet, genetic factors, epigenesis, homeostasis, and host-microbiome interactions, but not as established risk factors for infection in general.
The grounding supports treatment at a broad modality level only. It indicates that infections are generally managed with therapy directed at the infectious process, and that research includes immune-targeted approaches such as strategies aimed at HMGB1/TLR4 and the use of CRP as a marker of infection, but it does not provide a specific standard treatment class for all infections.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.